YEAR-END REPORT JANUARY-DECEMBER 2013 Summary: full-year

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 17, 2014 at 5:00 AM

YEAR-END REPORT JANUARY-DECEMBER 2013

Summary: full-year 2013 · Net sales increased by 47% to SEK 8,912k (6,080k). · Operating loss improved by SEK 4,196k to SEK 15,985k (loss: 20,181k), earnings per share improved to SEK -1.10 (-2.04). · Cash flow from operating activities was SEK -12,469k (-14,848k). · Genovis carried out two rights issues that raised about SEK 37.5 million before issue expenses. Summary: fourth quarter 2013 · Net sales changed marginally compared with the fourth quarter of 2012. · Operating loss improved by SEK 3,106k to SEK 5,385k (loss: 8,491k), earnings per share improved to SEK -0.34 (-0.70). · Cash flow from operating activities was SEK -1,502k (-3,889k). · Genovis launched two new products, FabULOUS and GlycINATOR for analysis and characterization of antibody molecules. · Genovis was granted SEK 1 million in research support from VINNOVA (the Swedish Agency for Innovation Systems) to explore a method for online process control in conjunction with manufacturing of the biological drug, mAbCHECK. · Genovis carried out a rights issue in December that raised about SEK 23.7 million before issue expenses. Comments from CEO Sarah Fredriksson 2013 is the first year that Genovis shows a positive earnings trend. I consider this achievement to be one of the most important milestones in the Company's development. Compared with 2012, sales rose 47 percent, while expenses increased on an annualized basis to 13 percent, primarily due to expenses for reorganization and continued investments in sales and marketing. Consequently, financial performance for the full year remains unchanged, though it improved over the first three quarters. I am not concerned about this variation over the quarters; in fact, I believe we will continue to see this trend in the future. We launched two new products in October. They were well-received by our customers and sales took off immediately, which speaks well of our R & D activities. During the fourth quarter, sales increased by about 70 percent in Europe compared with the same period last year, at the same time that we experienced a slowdown in the US market. We noted a cautious attitude in the US during the autumn amid general concerns about the economic situation. The US customers are at the forefront in the use of our products and they are heavily involved in completely new applications. Consequently I do not believe that interest is weakening, but rather the opposite and therefore believe this is a temporary decline. The reduced revenues in the US caused sales to remain unchanged in the fourth quarter compared with the same quarter in 2012, despite a strong increase in Europe. Expenses before depreciation and amortization rose 10 percent on a quarterly basis, with operating expenses increasing by 2.7 percent, while the rest are administrative costs of a nonrecurring nature. We had three objectives for 2013: to launch two new product lines, to substantially increase sales and for the protein products to become self -sufficient. We achieved the first two objectives and the products in the protein engineering portfolio generate sales that cover the costs of production, administration and sales and marketing activities, while also generating a contribution to research and development. While we did not quite achieve objective number three during the year, we made great strides in the right direction and will continue to do so in 2014. I believe we have every prospect for success in this endeavor. Sarah Fredriksson CEO, Genovis AB For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 sarah.fredriksson@genovis.com ABOUT GENOVIS Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: 46 (0)31-745 50 00

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nicely Network: A Game-Changer for B2B SaaS Marketing

Navigating the Reddit Marketing Labyrinth Life ain't a walk in the park for marketers these days, especially in the tech and SaaS arenas. Some folks seem to have cracked the code—or at least one part of it. Enter Nicely Network, which has just snagged the crown as the Best Reddit Marketing Agency for B2B SaaS & Software Companies, thanks to its knack for connecting...

Sobi Names Börje Ekholm as Chair Amid New Data

An Offbeat Choice for Chair? So, Sobi's gone and picked Börje Ekholm as the proposed Chair of their Board. Now, this might raise some eyebrows out there—Ekholm's no stranger to top roles, having steered the ship at Ericsson. The twist here is usually these Chair announcements hum along without much fanfare, but chuck in Ekholm and you get a bit of buzz—probably...

ASE Technology Shows Strong Growth in Q3 Financials

Taipei's Semiconductor Giant Surging Ahead You wanna talk about growth? ASE Technology Holding Co. just posted some fire results for their third quarter of 2026. Revenues screaming to NT$244,161 million, that's a tidy 44.8% jump year-over-year, and even 27.8% more than they grabbed last quarter. Call me old school, but I do love when a company's financials tell a tale of...

City National Grows with New Inglewood Branch

Inglewood, the New Banking Frontier It's not every day you see a bank banking on Inglewood, so to speak. Yet here we are. City National Bank is setting up shop in this buzzing part of Los Angeles, and it's high time someone paid attention to this vibrant hub. With major players in sports, entertainment, healthcare, and even aerospace calling Inglewood home, there's plenty...

Wabi's $1.25B Valuation: A New Era for AI?

By Logan Wright Updated Oct 29, 2026 Category News Views 171

A Major Milestone for Wabi Well, here we go—Wabi, the brainchild of Eugenia Kuyda, is stirring the pot with a massive $55 million funding round, pulling its valuation up to a hefty $1.25 billion. If you're raising eyebrows at that price tag, you’re not alone. It's a big number riding on an even bigger idea: that AI isn't just for solitary chats anymore, but for...

Digital Science's Game-Changing Jenni AI Acquisition

A Strategic Move in the Research Sector When you're dealing with tech giants and their endless race to corner niche markets, it's the big moves that really catch one's attention. The latest acquisition on the block is Digital Science picking up Jenni AI, a platform trusted by over 8 million students and researchers scattered across 189 countries. Now, that's a hefty user...

SKE Invigorates IRONWORKS London's Music Vibe With E-Cigs

Bringing SKE's Flair to London's Music Scene Well, folks, hold onto your hats—SKE's thrown its weight behind IRONWORKS London, extending its reach deeper into the UK's electronic music scene. This ain't just another gig; we're talking about the second time SKE is flexing its sponsorship muscles in the UK music arena, officially angling for the vape category spotlight....

Jack Henry's Q1 2027 Deconversion Revenue Hits $17.9M

Jack Henry Surprises with Strong Deconversion Revenue You're probably thinking, deconversion revenue—what on earth is that? Imagine you're in the financial tech business and one of your bigwig clients decides to merge or get gobbled up by another institution. They move shop, and voila, you've got some unexpected money flowing in due to that exit. That's deconversion...

Motiva's Q3 2026 Results: Strategic Moves Drive Growth

Strategic Transactions and Financial Highlights Motiva's third quarter of 2026 shows a company not just coasting but recalibrating its trajectory. Big moves had ripple effects on their financial landscape, most notably their sale of the Airport Platform, concluded for a hefty R$5.2 billion. Their portfolio's trimming isn't just a garage sale but a thought-out step...

Bandwidth Welcomes Chip Schroeder: Key Board Makeover

Turning the Page at Bandwidth Bandwidth Inc. (NASDAQ:BAND) just shook up its executive roster by bringing in a heavy hitter. Chip Schroeder's landing on the board is a bold move from a strategic player in the cloud communications space. This guy's not your average board member; he's a veteran navigator through stormy market waters, and at Bandwidth, it seems he'll be...